• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.骨髓瘤患者第三次接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的体液免疫和细胞免疫反应增强及病毒中和作用
Cancer Cell. 2022 May 9;40(5):441-443. doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6.
2
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.与多发性骨髓瘤患者对 SARS-CoV-2 二价加强疫苗免疫反应欠佳相关的细胞机制。
EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22.
3
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.抗 CD20 治疗史患者的体液和细胞免疫轨迹以及对第三剂 SARS-CoV-2 mRNA 疫苗的反应。
RMD Open. 2022 Mar;8(1). doi: 10.1136/rmdopen-2021-002166.
4
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.在 SARS-CoV-2 初免和既往感染人群中，BNT162b2 mRNA 疫苗对细胞和体液免疫应答的动力学和持久性：加强针和突破性感染的影响。
Front Immunol. 2022 May 31;13:863554. doi: 10.3389/fimmu.2022.863554. eCollection 2022.
5
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.接种 BNT162b2 双剂疫苗后第三剂 BNT162b2 与 ChAdOx1 对癌症患者的体液和细胞免疫对 SARS-CoV-2 的反应。
Clin Cancer Res. 2023 Feb 1;29(3):635-646. doi: 10.1158/1078-0432.CCR-22-2185.
6
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
7
Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.接种三剂 SARS-CoV-2 mRNA 疫苗后的细胞和体液免疫应答及突破性感染。
Front Immunol. 2022 Aug 17;13:981350. doi: 10.3389/fimmu.2022.981350. eCollection 2022.
8
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.深入分析特立氟胺或阿仑单抗治疗多发性硬化症患者对 COVID-19mRNA 疫苗接种的长期体液和细胞免疫反应。
Mult Scler Relat Disord. 2023 Apr;72:104616. doi: 10.1016/j.msard.2023.104616. Epub 2023 Mar 12.
9
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.血液透析患者中 SARS-CoV-2 mRNA 疫苗的细胞和体液免疫原性。
EBioMedicine. 2021 Aug;70:103524. doi: 10.1016/j.ebiom.2021.103524. Epub 2021 Aug 12.
10
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.免疫应答：SARS-CoV-2 mRNA 疫苗接种和加强剂在多发性骨髓瘤和单克隆丙种球蛋白病患者中的作用：Omicron 变异对体液免疫应答的影响。
Oncoimmunology. 2022 Sep 6;11(1):2120275. doi: 10.1080/2162402X.2022.2120275. eCollection 2022.

引用本文的文献

1
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.多发性骨髓瘤患者接种第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的体液和细胞免疫反应随访
Front Immunol. 2025 Feb 18;16:1532947. doi: 10.3389/fimmu.2025.1532947. eCollection 2025.
2
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.甘露糖修饰的脂质磷酸钙纳米颗粒疫苗通过调节肿瘤微环境增强抗肿瘤免疫反应。
J Funct Biomater. 2024 Aug 16;15(8):229. doi: 10.3390/jfb15080229.
3
Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments.根据B/T/NK淋巴细胞绝对计数和抗CD38治疗情况，多发性骨髓瘤“加强针”接种患者对SARS-CoV-2突破性感染的抗体反应
Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024022. doi: 10.4084/MJHID.2024.022. eCollection 2024.
4
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.血液系统恶性肿瘤患者和老年人群对三剂抗 SARS-CoV-2 BNT162b2 疫苗的体液和细胞反应动力学。
Front Immunol. 2024 Jan 26;14:1221587. doi: 10.3389/fimmu.2023.1221587. eCollection 2023.
5
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.接受三剂或更多剂抗SARS-CoV-2疫苗后多发性骨髓瘤患者突破性COVID-19的临床结局：一项64例的单中心分析
Ann Hematol. 2024 Jan;103(1):351-355. doi: 10.1007/s00277-023-05484-z. Epub 2023 Oct 2.
6
Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease.2022 年 12 月以来北京奥密克戎波期间浆细胞异常患者的 COVID-19 特征和结局：国家血液系统疾病临床医学研究中心的一项回顾性研究。
Ann Hematol. 2023 Oct;102(10):2857-2864. doi: 10.1007/s00277-023-05350-y. Epub 2023 Jul 12.
7
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.活动性多发性骨髓瘤患者对SARS-CoV-2 mRNA疫苗的体液和细胞反应的长期随访
Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023.
8
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
9
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
10
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia.浆细胞疾病患者对第二和第三次严重急性呼吸综合征冠状病毒 2 mRNA 疫苗的体液和细胞免疫反应。
Cancer Med. 2023 Jun;12(12):13135-13144. doi: 10.1002/cam4.5996. Epub 2023 Apr 26.

本文引用的文献

1
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.SARS-CoV-2 奥密克戎免疫逃逸和受体结合的结构基础。
Science. 2022 Feb 25;375(6583):864-868. doi: 10.1126/science.abn8652. Epub 2022 Jan 25.
2
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.新冠病毒mRNA加强疫苗对癌症患者抵御新冠病毒奥密克戎变种有很强的保护作用。
Cancer Cell. 2022 Feb 14;40(2):117-119. doi: 10.1016/j.ccell.2021.12.014. Epub 2021 Dec 30.
3
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
4
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
5
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
6
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.辉瑞-BioNTech 疫苗加强针在以色列预防新冠病毒。
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.
7
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.COVID-19 疫苗接种后骨髓瘤患者的中和抗体反应高度依赖于抗骨髓瘤治疗的类型。
Blood Cancer J. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3.
8
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
9
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.mRNA 疫苗在癌症患者中的免疫原性。
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
10
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.

作者信息

Aleman Adolfo, Van Oekelen Oliver, Upadhyaya Bhaskar, Beach Katherine, Kogan Zajdman Ariel, Alshammary Hala, Serebryakova Kseniya, Agte Sarita, Kappes Katerina, Gleason Charles R, Srivastava Komal, Almo Steve, Cordon-Cardo Carlos, Krammer Florian, Merad Miriam, Jagannath Sundar, Wajnberg Ania, Simon Viviana, Parekh Samir

机构信息

Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Cancer Cell. 2022 May 9;40(5):441-443. doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6.

DOI:10.1016/j.ccell.2022.03.013
PMID:35390296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8983835/
Abstract
摘要